Effectiveness Of Erythropoietin and Darbepoetin in The Treatment of Chronic Kidney Disease- Associated Anemia

Anemia is a common hematologic disorder affecting up to one-third of pregnant women.  Anemia is categorized by etiology (i.e., acquired or inherited), mechanism (i.e. decreased red blood cell production or increased red blood cell destruction), and red blood cell size (i.e. microcytic, macrocytic, or normocytic [1].   The National Kidney Foundation of The United States of America defines chronic kidney disease (CKD) as a evidence of kidney damage based on abnormal urinalysis results (eg, proteinuria, haematuria) or structural abnormalities observed on ultrasound images or an absolute glomerular filtraion rate (GFR) of less than 60 mL/min for 3 or more month.Erythropoietin deficiency is the most significant cause of anemia in CKD and has been demonstrated to occur at each stage of kidney failure. Because the kidney is the sole source of erythropoietin (EPO) synthesis in adults, reduction in kidney mass as occurs in progressive CKD often results in impairment of EPO production, resulting in anemia.[2]    Anaemia in patients with chronic kidney disease (CKD) is a common complication that has been associated with poor outcomes such as cardiovascular complications and mortality . Erythropoiesis-stimulating agents (ESAs) have been available for almost two decades and remain the central strategy for the treatment of anaemia in patients with CKD. Anaemia management is rapidly evolving, as new trial designs and an increasing number of treatment options continue to advance the understanding of Hb control in patients with CKD. Clearly, maintaining patients within target Hb ranges is more important than ever, and the ability of ESAs to contribute to Hb control will be under new scrutiny.[3]  One of the major challenges for management of CKD in India is late presentation of patients to the nephrologist. Indian CKD registry reported close to 48% patients presenting in stage V[4].   The dysfunction of erythropoietin (EPO) production because of declining renal function is the major cause of anaemia in patients with chronic renal failure. Therefore, dialysis patients with anaemia have an increased risk for cardiovascular morbidity and mortality [5].       The major difference between erythropoietin and darbepoetin is their half-life, Darbepoetin has three-time higher half-life compared to erythropoietin, therefore can be administered less frequently. This is because of an addition of N-linked carbohydrate groups, which reduces its affinity to EPO receptor and thus prolonging circulation time [6]. Anemia in children is defined based on the 2012 KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease, with haemoglobin (Hb) cut-off levels varying based on age and sex [2].

           Evidence from the North American Paediatric Renal Trials and Collaborative Studies (NAPRTCS) cohort consistently reveals an escalating risk of anemia with the progression of CKD stages.[7].  Darbepoetin (DPO) is a novel erythropoiesis-stimulating protein (NESP) that is a recombinant hyperglycosylated analogue of epoetin which stimulates red blood cell production by the same mechanism as the endogenous hormone Produced by recombinant DNA technology [8].  Clinical studies have shown that darbepoetin with a reduced dose frequency (once a week or biweekly) for treating anemia in CKD patients has similar efficacy and safety as epoetin benefiting both patients and health care staff [9]. Darbepoetin (DPO) is a novel erythropoiesis-stimulating protein (NESP) that is a recombinant hyperglycosylated analogue of epoetin which stimulates red blood cell production by the same mechanism as the endogenous hormone Produced by recombinant DNA technology.[8]          Anemia of CKD is highly associated with adverse comes such as cardiovascular events and increased mortality. Additionally, the severity of anemia correlates with decreased quality of life and increased hospitalizations. Understanding the diverse mechanisms involved, recommended treatment guidelines, and new therapeutic developments is crucial for managing this condition effectively [ 10]. Endogenous erythropoietin (EPO), the primary regulator in the production of red blood cells, is a glycoprotein hormone produced by the kidneys in response to hypoxia and anemia. There is a physiologic rise in EPO levels during pregnancy, which increases red blood cell production. Recombinant EPO (rEPO) is a synthetic version of this hormone derived from Chinese hamster ovarian cells. Historically, rEPO use in pregnancy has been limited to pregnant patients with anemia secondary to end- stage renal disease.[1] Early recognition, timely management with appropriate therapy helps to reduce the complications of anemia. Erythropoiesis-stimulating agents (ESAs) are one of the important measures for correction of anemia in CKD patients. Darbepoetin, an ESA is a valuable therapeutic option for the treatment of anemia in CKD patients and has played a vital role in enhancing anemia management.[4] The most common use is in people with anaemia (low blood count) related to kidney dysfunction. When the kidneys are not properly functioning, they produce less than normal amounts of erythropoietin, which can lead to low red blood cell production, or anaemia. Erythropoietin triggers the bone marrow to increase red blood cell production.[8]

AIM

To compare the therapeutic outcomes of erythropoietin and darbepoetin in chronic kidney disease patients with anemia.

OBJECTIVE

• To evaluate the improvement in hemoglobin levels following treatment with erythropoietin and darbepoetin.
• To assess the safety and adverse effect profiles of erythropoietin and darbepoetin.
• To compare the dosing frequency and treatment compliance associated with erythropoietin and darbepoetin.

METHODOLOGY

STUDY TYPE

• It was a prospective comparative study

STUDY DURATION

• The study was conducted from July 2025 to December 2025 among patients with anemia associated with chronic kidney disease.

INCLUSION CRITERIA

• Patients aged 18-97 years
• Patient diagnosed CKD associated Anemia
• Patients receiving either Erythropoietin or Darbepoetin therapy

EXCLUSION CRITERIA

• Pediatric patients were excluded
• Patients with Anemia due to other causes were excluded
• Patients who are taking other combination drugs

STUDY PROCEDURE

• A total of 100 patients who met the predefined inclusion and exclusion criteria were selected and randomly divided into two equal groups based on their treatment regimen. Group A consisted of 50 patients who received Erythropoietin 4000 units administered subcutaneously twice weekly, while Group B consisted of 50 patients who received Darbepoetin alfa 40 mcg administered subcutaneously once monthly. Throughout the study period, data pertaining to drug administration along with laboratory investigations including Red Blood Cell (RBC) count, Packed Cell Volume (PCV), and Hemoglobin (Hb) levels were systematically collected and recorded at regular intervals. In addition, any adverse drug reactions (ADRs) observed or reported in relation to either of the study drugs were carefully identified and documented. The laboratory parameters comprising RBC count, PCV, and Hemoglobin levels were employed to evaluate and compare the efficacy of both treatment regimens, whereas the incidence and nature of the reported ADRs were used to assess and compare the safety of both drugs. All data collected throughout the study were subsequently tabulated and statistically analyzed using the z-test to determine the level of significance between the two treatment groups.

RESULTS:

• The study comprised of 100 patients, with 50 patients in each group. Demographic variables were assessed. The maximum number of patients were aged between 58–77 years, with male gender predominance. In both groups, most of the patients were having stage 5 CKD.

 

 

Figure 1: Haemoglobin before vs after treatment Erythropoietin vs Darbepoetin

 

 

Figure 2: RBC count before vs after Treatment Erythropoietin vs Darbepoetin

 

 

Figure 3: Packed cell volume before vs after Treatment Erythropoietin vs Darbepoetin

 

 

Figure 4: Adverse events reported by patients on Erythropoietin

 

 

Figure 5: Adverse Events reported by patients on Darbepoetin

Figure 5 shows the adverse events reported by patients receiving darbepoetin. Among the patients, 36% experienced hypertension (HTN), while 64% did not report any adverse events. No other adverse events were observed in the darbepoetin group. The graph indicates that most patients tolerated darbepoetin well, with hypertension being the only reported adverse event.

EFFICACY ASSESSMENT:

The efficacy of treatment was assessed by evaluating changes in haemoglobin (Hb), red blood cells (RBCs), and packed cell volume (PCV) in both groups before and after therapy.

Prior to treatment, the mean ± SD haemoglobin level was 7.8 ± 1.3 g/dL in the erythropoietin (EPO) group and 8.5 ± 1.2 g/dL in the darbepoetin group. Following treatment, haemoglobin levels increased to 9.0 ± 1.4 g/dL and 9.7 ± 1.3 g/dL, respectively. The mean rise in haemoglobin was 1.2 g/dL in both groups, demonstrating a highly significant improvement (p < 0.0001).

Similarly, the mean ± SD RBC count before treatment was 2.7 ± 0.5 million cells/mm³ in the EPO group and 3.0 ± 0.6 million cells/mm³ in the darbepoetin group. Post-treatment values increased to 3.2 ± 0.5 and 3.4 ± 0.6 million cells/mm³, respectively. The mean increase in RBC count was 0.5 in the EPO group and 0.4 in the darbepoetin group, both of which were statistically significant (p < 0.0001).

The mean ± SD PCV levels prior to treatment were 24 ± 4.2% in the EPO group and 26 ± 4.0% in the darbepoetin group. After treatment, PCV values rose to 27.5 ± 4.5% and 29.5 ± 4.0%, respectively. The mean increase in PCV was 3.5% in both groups, with statistically significant improvement (p < 0.0001).

Overall, both erythropoietin and darbepoetin treatments resulted in significant improvements in haematological parameters, with comparable efficacy observed between the two groups.

SAFETY ASSESSMENT:

Along with efficacy, the safety profile of both treatment groups was evaluated by monitoring adverse drug reactions.

Hypertension emerged as the most frequently observed adverse event in both groups. It was reported in 19 patients (38%) in the erythropoietin (EPO) group and in 18 patients (36%) in the darbepoetin group.

In the EPO group, additional adverse effects included headache, joint pain, and vomiting, each occurring in 2% of patients. These events were mild and did not necessitate discontinuation of treatment.

In the darbepoetin group, no other significant adverse events were noted apart from hypertension.

Overall, the frequency and nature of adverse effects were comparable between the two groups, suggesting that erythropoietin and darbepoetin exhibit similar safety profiles.

DISCUSSION

The present study was undertaken to compare the efficacy and safety of erythropoietin (EPO) and darbepoetin in the treatment of anemia among patients with chronic kidney disease (CKD). Anemia is a frequent complication of CKD, mainly resulting from decreased endogenous erythropoietin production, shortened red blood cell (RBC) lifespan, and nutritional deficiencies. Appropriate management of anemia is crucial for improving quality of life, reducing cardiovascular risk, and slowing disease progression.

In this study, both treatment groups showed statistically significant improvements in haemoglobin (Hb), RBC count, and packed cell volume (PCV) following therapy. The mean increase in haemoglobin was 1.2 g/dL in both groups, indicating that erythropoietin and darbepoetin are equally effective in stimulating erythropoiesis. This improvement reflects a favourable bone marrow response to erythropoiesis-stimulating agents (ESAs), leading to enhanced oxygen-carrying capacity.

RBC counts also improved significantly in both groups, with a slightly greater increase observed in the EPO group (0.5) compared to the darbepoetin group (0.4). However, this minor numerical difference is not clinically significant, suggesting similar efficacy between the two treatments. The rise in RBC count further supports the role of ESAs in promoting the proliferation and differentiation of erythroid progenitor cells.

Similarly, PCV levels increased by 3.5% in both groups, demonstrating consistent improvement across all haematological parameters. The parallel rise in Hb, RBC, and PCV indicates a uniform and effective correction of anemia in both treatment groups.

From a pharmacological standpoint, both erythropoietin and darbepoetin act by stimulating erythropoietin receptors in the bone marrow. Darbepoetin, however, has a longer half-life due to the presence of additional sialic acid residues, allowing for less frequent dosing. Despite this pharmacokinetic advantage, the present findings indicate that both agents provide comparable clinical efficacy, consistent with previous studies.

Regarding safety, hypertension was the most commonly reported adverse event in both groups, occurring in 38% of patients receiving EPO and 36% of those receiving darbepoetin. This is a known class effect of ESAs, likely due to increased blood viscosity and vascular resistance associated with rapid correction of anemia. Other adverse events such as headache, joint pain, and vomiting were reported only in a small proportion of patients in the EPO group and were mild in severity.

Importantly, no serious adverse events or treatment discontinuations were observed, indicating that both therapies were well tolerated. The similar incidence of adverse effects in both groups suggests comparable safety profiles, supporting their use in the long-term management of CKD-associated anemia.

An additional consideration is the clinical convenience offered by darbepoetin. Its longer duration of action allows for reduced dosing frequency, which may enhance patient compliance and convenience, particularly in outpatient settings. However, in terms of efficacy, both agents demonstrate equivalent therapeutic benefits.

The study has certain strengths, including the direct comparison of two commonly used ESAs using standardized haematological parameters. Nevertheless, limitations such as a relatively small sample size and short follow-up period may affect the generalizability of the results. Further long-term studies are warranted to assess sustained efficacy, cardiovascular outcomes, and cost-effectiveness.

CONCLUSION

Erythropoietin and Darbepoetin were effective in the treatment of anemia associated with chronic kidney disease. No significant difference was observed in the improvement of haemoglobin, Red blood cell count, and haematocrit levels between the two groups, indicating comparable therapeutic efficacy. Adverse events were reported in both groups; however, a lower incidence was observed with Darbepoetin, suggesting a comparatively better safety profile. Therefore, Darbepoetin may be considered a preferable treatment option, while Erythropoietin remains an effective and well-tolerated alternative.

REFERENCES

1. Georgieff MK. Iron deficiency in pregnancy. Am J Obstet Gynecol. 2020;223(4):516-524.
2. Sienas L, Wong T, Collins R, Smith J. Contemporary uses of eryth ropoietin in pregnancy: a literature review. Obstet Gynecol Surv. 2013;68(8):594-602.
3. Drueke TB, Locatelli F, Clyne N, et al. 2006. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 355:2071–84
4. Le Meur Y, Lorgeot V, Comte L, et al. 2001. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis, 38:510–7.
5. Foley RN, Parfrey PS, Harnett JS et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. AmJKidney Dis 1996; 28: 53–61
6. Lenkhorst CE, Wish JB. Anemia in renal disease: Diagnosis and management. Blood Reviews. 2010;24:39-47.
7. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Frontiers in Medicine. 2021;Volume 8 - 2021.
8. Dhayef AK, Manuti JK, Abutabiekh AS. Anemia response to Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney disease on Hemodialysis. Methods. 2017;17:19.
9. Obrador GT, Macdougall IC (2013) Effect of red cell transfu sions on future kidney transplantation. Clin J Am Soc Nephrol 8(5):852–860.
10. Bello K. complication of chronic kidney disease: current state, knowledge gapss and strategy for action. Kis. 2017;7:122-9.
11. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemotherapy. 2013;40(5):302–9.
12. Schmid H. Cost‐effectiveness of continuous erythropoietin re ceptor activator in anemia. Clinicoecon Outcomes Res. 2014;6: 319‐330.